CN Patent

CN106029632B — 酰胺衍生物

Assigned to Tohoku University NUC · Expires 2019-06-21 · 7y expired

What this patent protects

本发明提供一种对包含癌的起因于OPN产生亢进的疾病的治疗和/或预防有用的治疗剂，其包含由下式表示的化合物或其医药上所允许的盐。 [式中，R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、m、n、p、X及Y与说明书中的定义相同。]

USPTO Abstract

本发明提供一种对包含癌的起因于OPN产生亢进的疾病的治疗和/或预防有用的治疗剂，其包含由下式表示的化合物或其医药上所允许的盐。 [式中，R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、m、n、p、X及Y与说明书中的定义相同。]

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: CN106029632B
Jurisdiction: CN
Classification: —
Expires: 2019-06-21
Drug substance claim: No
Drug product claim: No
Assignee: Tohoku University NUC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.